Erenumab: First Global Approval

@article{Markham2018ErenumabFG,
  title={Erenumab: First Global Approval},
  author={Anthony Markham},
  journal={Drugs},
  year={2018},
  volume={78},
  pages={1157-1161}
}
  • Anthony Markham
  • Published 2018
  • Medicine
  • Drugs
  • Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)—a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist—for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in migraine frequency in phase II and III clinical trials. Based on these positive results erenumab was recently approved in the US for the preventive… CONTINUE READING

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 10 CITATIONS

    Monoclonal antibodies for the prevention of migraine

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 15 REFERENCES

    A Controlled Trial of Erenumab for Episodic Migraine

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    Erenumab (AMG 334) in episodic migraine

    VIEW 5 EXCERPTS
    HIGHLY INFLUENTIAL

    ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: results from the Phase 3b LIBERTY study [abstract no. 009

    • U Reuter, P Goadsby, M Lanteri-Minet
    • American Academy of Neurology 70th Annual Meeting
    • 2018
    VIEW 5 EXCERPTS
    HIGHLY INFLUENTIAL

    AMG 334) in episodic migraine: interim analysis of an ongoing open-label study

    • M Ashina, D Dodick, P J Goadsby
    • Neurology
    • 2017

    Amgen announces expanded commercial collaboration with novartis for erenumab in migraine

    • Amgen Inc
    • [media release]
    • 2017
    VIEW 1 EXCERPT